Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma 2Glioma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Paraproteinemias 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Neuroepithelial 1Neoplasms 1Multiple Myeloma 1Medulloblastoma 1Lymphoproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Hodgkin Disease 1Hematologic Diseases 1Head and Neck Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 8X-Rays 7Phantoms, Imaging 7Cyclophosphamide 7Specimen Handling 6Nuclear Medicine Department, Hospital 5fludarabine 4Etoposide 4Biopsy 4tazemetostat 3etoposide phosphate 3Vincristine 3Temozolomide 3Nivolumab 3Cisplatin 3Carboplatin 3Automobiles 3ulixertinib 2tipifarnib 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Topotecan 2Sirolimus 2Methotrexate 2Mesna 2LY3023414 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdoid Tumor × CLR1404 × 1 year × Clear all
NCT03478462 2026-03-18

CLOVER-2

Cellectar Biosciences, Inc.

Phase 1 Active not recruiting
30 enrolled
CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡